Gates Foundation is currently accepting applications for its Innovations in Cost-Disruptive Tools for Diagnosis and Screening 2026. Interested applicants are encouraged to click here to learn more about this opportunity and apply for it.
About Gates Foundation Innovations in Cost-Disruptive Tools for Diagnosis and Screening
The Gates Foundation challenge seeks innovative solutions that lower the cost of diagnostic and screening tools for low-resource settings. The program emphasizes technologies that can achieve near-zero incremental cost per test while addressing high-priority disease areas. Applicants are encouraged to propose transformative approaches that integrate advanced sensing, artificial intelligence, software, and platform-based models for scalable, sustainable, and effective deployment.
Benefits of Gates Foundation Innovations in Cost-Disruptive Tools for Diagnosis and Screening
The initiative supports a diverse portfolio of projects ranging from:
- Early-stage, high-risk, high-reward concepts
- Advanced solutions ready for adaptation and scaling
Applicants should provide a clear workplan with milestones, aligned to the maturity of their technology and deployment readiness. Funding supports innovation that can dramatically reduce diagnostic costs while enabling population-scale impact in low- and middle-income countries.
Gates Foundation Innovations in Cost-Disruptive Tools for Diagnosis and Screening Requirements
Eligible applicants include:
- Research institutes and academic institutions
- Nonprofit organizations and international organizations
- For-profit companies and government agencies
Applicants must comply with global access requirements and commit to independent evaluation, ethical practices, and regulatory standards
Application Date and Process
- Click on the link to the application website to apply.
Application Deadline
28 April, 2026
Opportunity Application
View details of
Gates Foundation Innovations in Cost-Disruptive Tools for Diagnosis and Screening
Apply for Gates Foundation Innovations in Cost-Disruptive Tools for Diagnosis and Screening
🔍
